Pharvaris B.V. (PHVS) Stock Forecast & Price Target

Pharvaris NV has raised its global peak sales estimate for deucrictibant to $1.65 billion by 2037, reflecting increased confidence in its market potential following positive results from Phase 2 studies. Notably, 100% of participants in the open-label extension achieved "well-controlled HAE" status, indicating substantial quality of life improvements and effectiveness of the treatment. Additionally, with an estimated prevalence of 1:100,000 to 1:500,000 and no approved therapies currently available, deucrictibant is positioned to capture significant market share if approved, enhancing its long-term financial outlook.

Pharvaris NV faces a challenging landscape in the development of deucrictibant, primarily due to the inadequately de-risked nature of bradykinin B2 receptor antagonism within the chronic prophylaxis setting. The highly competitive HAE market is dominated by established therapies and segment leaders, which may pose significant hurdles for Pharvaris to gain traction. Additionally, the impending approval of multiple subcutaneous therapies over the next three years could further undermine Pharvaris's market share and limit the uptake of deucrictibant.